Patents by Inventor Huali LI

Huali LI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION FOR INHALATION
    Publication number: 20240082203
    Abstract: The present invention relates to a pharmaceutical composition for inhalation, comprising N-[2-[[[4-(2,2-dimethyl-1-oxopropoxy)phenyl]sulfonyl]amino]benzoyl]-(S)-glycinate sodium or a hydrate thereof, a pH adjuster, an osmotic pressure adjuster, and optionally a surfactant. The pharmaceutical composition for inhalation of the present invention can improve drug stability. After being atomized by an inhalation atomizing device, inhalation droplets can maintain good uniformity.
    Type: Application
    Filed: December 29, 2021
    Publication date: March 14, 2024
    Applicants: SHANGHAI HUILUN PHARMACEUTICAL CO., LTD., SHANGHAI HUILUN JIANGSU PHARMACEUTICAL CO., LTD.
    Inventors: Changjun LI, Wenhua LI, Jihong QIN, Huali LIU, Jinfeng LI, Xiangjiang NIE
  • Tetramaleimide linkers and use thereof
    Patent number: 11666623
    Abstract: The present invention is directed to tetramaleimide linkers and use thereof, more specifically to the compounds represented by formula I and their use in the preparation of antibody-drug conjugates (ADCs). The ADCs obtained from the tetramaleimide linkers have high homogeneity and stability, and could be used effectively for the treatment of various diseases including tumors. The definition of the groups in formula I is the same as that in the description.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: June 6, 2023
    Assignee: NewBio Therapeutics, Inc.
    Inventors: Deqiang An, Nianhe Han, Peng Zhu, Di Zeng, Baoxiang Wang, Huali Li, Chun Yang
  • Oxadiazole linkers and use thereof
    Patent number: 11241503
    Abstract: The present invention is directed to oxadiazole linkers and use thereof, more specifically to the compounds represented by formula I, II, and III, and their use in the preparation of antibody-drug conjugates (ADCs). The ADCs obtained from said oxadiazole linkers have high homogeneity and stability, and could be used effectively for the treatment of various diseases including tumors. The definition of the groups in formula I, II, and III is the same as that in the description.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: February 8, 2022
    Assignee: NewBio Therapeutics, Inc.
    Inventors: Nianhe Han, Deqiang An, Di Zeng, Baoxiang Wang, Huali Li, Hang Chen, Chun Yang
  • Anti-CD79b Antibodies, Drug Conjugates, and Applications Thereof
    Publication number: 20210388082
    Abstract: Disclosed herein is an anti-CD79b antibody or antigen-binding fragment thereof, a drug conjugate thereof and use thereof. The anti-CD79b antibody or antigen-binding fragment thereof herein comprises: HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and LCDR3 comprising the amino acid sequence of SEQ ID NO: 6.
    Type: Application
    Filed: October 31, 2019
    Publication date: December 16, 2021
    Inventors: Nianhe HAN, Liwei SONG, Deqiang AN, Di ZENG, Huali LI, Chun YANG
  • OXADIAZOLE LINKERS AND USE THEREOF
    Publication number: 20210154320
    Abstract: The present invention is directed to oxadiazole linkers and use thereof, more specifically to the compounds represented by formula I, II, and III, and their use in the preparation of antibody-drug conjugates (ADCs). The ADCs obtained from said oxadiazole linkers have high homogeneity and stability, and could be used effectively for the treatment of various diseases including tumors. The definition of the groups in formula I, II, and III is the same as that in the description.
    Type: Application
    Filed: June 4, 2018
    Publication date: May 27, 2021
    Inventors: Nianhe HAN, Deqiang AN, Di ZENG, Baoxiang WANG, Huali LI, Hang CHEN, Chun YANG
  • TETRAMALEIMIDE LINKERS AND USE THEREOF
    Publication number: 20210128668
    Abstract: The present invention is directed to tetramaleimide linkers and use thereof, more specifically to the compounds represented by formula I and their use in the preparation of antibody-drug conjugates (ADCs). The ADCs obtained from the tetramaleimide linkers have high homogeneity and stability, and could be used effectively for the treatment of various diseases including tumors. The definition of the groups in formula I is the same as that in the description.
    Type: Application
    Filed: April 18, 2018
    Publication date: May 6, 2021
    Inventors: Deqiang AN, Nianhe HAN, Peng ZHU, DI ZENG, Baoxiang WANG, Huali LI, Chun YANG